CD8A and cancer: Consistent with this, studies enhancing the production of IFN-γ by CD8 T cells have shown improved antitumor responses in vivo in several mouse models of cancer [6, 7], and the robust activation of human CD8 T cells, including an IFN-γ molecular signature, are thought to underlie the recent successes of checkpoint inhibitors in cancer treatment [8].